Third Rock seeds cell ther­a­py start­up with $95M in bid to cure MS

In 2018, for­mer Bio­gen ex­ec­u­tives Saman­tha Singer and Richard Ran­so­hoff were work­ing with Third Rock on a new way to treat au­toim­mune dis­eases when one of the VC’s part­ners asked what Ran­so­hoff thought of a wild­ly dif­fer­ent ap­proach to tack­ling those be­dev­il­ing dis­or­ders.

Third Rock want­ed to build a com­pa­ny that would turn a pro­tec­tive class of im­mune cells called reg­u­la­to­ry T cells in­to ther­a­pies, and an­oth­er team had spent the last year and a half try­ing to find the best con­di­tion it would work for. Fi­nal­ly, they set­tled on mul­ti­ple scle­ro­sis, a dis­ease Ran­so­hoff had stud­ied for three decades as an aca­d­e­m­ic. They want­ed his opin­ion: What do you think?

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.